SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Malik Muhammad Shahbaz | Senior VP, BAS | 2026-10-16 | Open-market buy | 479 | $25K |
| BAILLY R JEFFREY | Director | 2026-10-07 | Open-market buy | 10000 | $500K |
| Ogunsanya Gregory O. | Sr. VP, GC and Corp Secretary | 2026-10-04 | Option exercise | 453 | $23K |
| Ogunsanya Gregory O. | Sr. VP, GC and Corp Secretary | 2026-10-04 | Option exercise | 202 | $10K |
| Ogunsanya Gregory O. | Sr. VP, GC and Corp Secretary | 2026-10-04 | Grant/award | 19 | $954 |
| Ogunsanya Gregory O. | Sr. VP, GC and Corp Secretary | 2026-10-04 | Tax withholding | 61 | $3K |
| Ogunsanya Gregory O. | Sr. VP, GC and Corp Secretary | 2026-10-04 | Tax withholding | 141 | $7K |
| Martin Celine Christine | Director | 2026-09-30 | Open-market buy | 465 | $23K |
| Happe Michael J | Director | 2026-09-29 | Open-market buy | 2000 | $99K |
| Lauber Charles T | Director | 2026-09-29 | Open-market buy | 2005 | $100K |
| Zaheer Srilata | Director | 2026-09-29 | Open-market buy | 40 | $2K |
| FLORNESS DANIEL L | Director | 2026-09-28 | Open-market buy | 2030 | $100K |
| HANDLEY THOMAS W | Director | 2026-09-28 | Open-market buy | 2000 | $99K |
| Rasmussen Trangsrud Teresa J | Director | 2026-09-28 | Open-market buy | 1542 | $75K |
| Rasmussen Trangsrud Teresa J | Director | 2026-09-28 | Open-market buy | 500 | $24K |
| Zaheer Srilata | Director | 2026-09-28 | Open-market buy | 2000 | $98K |
| Weaver Nathan D. | Exec VP, Business Transform. | 2026-08-11 | Option exercise | 4976 | $249K |
| Weaver Nathan D. | Exec VP, Business Transform. | 2026-08-11 | Option exercise | 4585 | $246K |
| Weaver Nathan D. | Exec VP, Business Transform. | 2026-08-11 | Open-market sell | 9561 | $593K |
| Magalhaes Joao | Sr. VP, Engineering Adhesives | 2026-07-09 | Option exercise | 1658 | $83K |
H.B. Fuller Company completed the issuance and sale of $850 million in aggregate principal amount of 7.625% Notes due 2034. The notes represent a material new direct financial obligation that significantly affects the company's capital structure and financial obligations.
View raw filing on EDGAR →The disclosure centers on H.B. Fuller's Board rejection of Ancora Holdings' second unsolicited proposal to acquire the Building Adhesive Solutions business for $1.2–$1.4 billion, coupled with the Company's announcement of a market check for select business segments with intent to use proceeds for deleveraging. While the immediate action is a rejection, the material event is the M&A activity—the unsolicited acquisition proposal and the Company's responsive strategic review process involving potential divestitures. This is a significant capital allocation and portfolio restructuring decision that would affect a reasonable investor's assessment of the registrant's strategy and financial position.
View raw filing on EDGAR →The filing discloses two events: Ruth S. Kimmelshue's resignation as a director effective immediately, and R. Jeffrey Bailly's election to the Board as a Class I director effective September 23, 2026. While both a departure and an appointment occur, the principal disclosed action centers on Bailly's appointment, which is emphasized throughout the filing and press release as bringing "highly relevant operating and leadership experience" and "valuable expertise in medical technologies" to support the Company's strategic repositioning. The appointment is material to investors as it reflects a deliberate Board composition change aligned with the Company's strategic priorities.
View raw filing on EDGAR →H.B. Fuller Company announced its third quarter 2026 operating results on September 23, 2026, disclosing net revenue of $938 million (up 5.2% YoY), net income of $79 million, adjusted EBITDA of $187 million (up 9% YoY), and adjusted diluted EPS of $1.52 (up 21% YoY). The press release is furnished as Exhibit 99.1 and includes detailed financial statements, segment performance, balance sheet metrics, and updated fiscal 2026 guidance. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →H.B. Fuller entered into Amendment No. 3 to its credit agreement on July 17, 2026, refinancing $420 million in term A loans and $700 million in revolving loans, increasing the revolving facility by $100 million to $800 million total, and extending maturity to July 17, 2031 with improved terms including a 25 basis point margin reduction.
View raw filing on EDGAR →H.B. Fuller terminated its $2.086 billion Secured Bridge Credit Agreement dated June 25, 2026, with no outstanding loans at termination and all commitments cancelled, signaling completion of an underlying refinancing or transaction.
View raw filing on EDGAR →H.B. Fuller announced a recommended cash offer to acquire Advanced Medical Solutions Group plc for £2.85 per share (£715 million enterprise value), with boards of both companies having reached agreement. The transaction includes approximately $3 billion in committed bridge financing, is expected to add ~$300 million in annual revenues with ~$55 million in run-rate synergies, and is subject to shareholder approval and regulatory clearance with expected close by year-end 2026.
View raw filing on EDGAR →H.B. Fuller Company disclosed its second quarter 2026 operating results via press release on June 24, 2026, reporting net revenue of $950 million (up 5.8% YoY), net income of $68 million, adjusted EPS of $1.41 (up 19% YoY), and adjusted EBITDA of $181 million (up 9% YoY). The company also updated full-year fiscal 2026 guidance, increasing the midpoint of adjusted EBITDA and adjusted EPS guidance. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the registrant's financial performance and forward outlook.
View raw filing on EDGAR →